Skip to main content
Fig. 2 | Health Economics Review

Fig. 2

From: The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Fig. 2

Hypotheses to be tested. The figure visualizes the hypotheses to be tested according to the study design of the submitted evidence for the oncology products for which an added benefit was granted by the Federal Joint Committee and a negotiated reimbursement amount is available in the period under consideration

Back to article page